Source comparison
Tesamorelin + Ipamorelin Blend for Anti-Aging: Protocol Comparison
Different research applications require different dosing strategies. The table below compares three common protocols for the tesamorelin + ipamorelin blend for anti-aging based on dosing frequency, target IGF-1 elevation, and practical considerations. | Protoc
This comparison does not assign a generated winner or score.
- Different research applications require different dosing strategies. The table below compares three common protocols for the tesamorelin + ipamorelin blend for anti-aging based on dosing frequency, target IGF-1 elevation, and practical considerations.
- | Protocol Type | Tesamorelin Dose | Ipamorelin Dose | Frequency | Target IGF-1 Elevation | Practical Consideration | Professional Assessment ||—|—|—|—|—|—|| Conservative Restoration | 1mg | 200mcg | Once daily (before bed) | 40–55% from baseline | Lowest side effect incidence; appropriate for individuals with baseline IGF-1 <140 ng/mL | Best starting protocol for first 8–12 weeks; allows assessment of individual response before escalation || Moderate Enhancement | 1.5–2mg | 250–300mcg | Once daily (before bed) | 55–70% from baseline | Produces measurable body composition changes (VAT reduction, lean mass gain) within 12–16 weeks | Optimal for sustained use once tolerance is established; most research applications use this range || Intensive Restoration | 2mg | 300mcg | Once daily + optional AM microdose (0.5mg/100mcg) | 70–85% from baseline | Twice-daily dosing increases injection site reactions; diminishing returns above single daily dose | Reserved for short-term protocols (8–12 wee
- The bottom line: once-daily administration before sleep at the moderate dose range (1.5–2mg tesamorelin + 250–300mcg ipamorelin) produces the most consistent IGF-1 elevation with the lowest incidence of side effects. Splitting doses throughout the day disrupts the circadian pulse pattern the protocol is designed to restore and increases receptor desensitization risk. Protocols under 1mg/200mcg rarely achieve statistically significant IGF-1changes; protocols exceeding 2mg/300mcg produce side effects—primarily water retention, carpal tunnel symptoms, and mild insulin resistance—that outweigh marginal additional benefit.